StockMacro
Menu

Johnson & Johnson

Institutional investment manager (13F filer) CIK 200406Name as filed: JOHNSON & JOHNSONIts filings on EDGARAll funds

Measures activity, not value. Not investment advice.

Reported $761.7M in 13 companies we cover at the end of Q3 2026; opened 0 positions and sold out of 0; largest position: Protagonist Therapeutics, $345.1M (45% of the reported value).

Reported value, Q3 2026 The total market value the manager reported on Form 13F for the quarter end, in dollars, including companies outside our coverage. 13F lists long positions in US-listed shares and options only, and is filed up to 45 days after the quarter ends.
$761.7M
Positions in companies we cover
13
Their share of the reported value
75%
Report filed
26 Oct 2026
Reported value per quarter, Q3 2021 to Q3 2026
Q3 2021: $1.1B, 14 positionsQ4 2021: $878.4M, 14 positionsQ1 2022: $529.0M, 13 positionsQ2 2022: $391.5M, 13 positionsQ3 2022: $339.8M, 13 positionsQ4 2022: $0, 13 positionsQ1 2023: $307.4M, 14 positionsQ2 2023: $322.1M, 13 positionsQ3 2023: $271.5M, 14 positionsQ4 2023: $4.4B, 14 positionsQ1 2024: $4.4B, 14 positionsQ2 2024: $400.7M, 17 positionsQ3 2024: $427.3M, 16 positionsQ4 2024: $386.1M, 17 positionsQ1 2025: $341.9M, 17 positionsQ2 2025: $334.1M, 17 positionsQ3 2025: $503.9M, 17 positionsQ4 2025: $555.0M, 15 positionsQ1 2026: $652.4M, 14 positionsQ2 2026: $798.7M, 13 positionsQ3 2026: $761.7M, 13 positions

Q3 2021Highest $4.4BQ3 2026

Every quarter
QuarterReported valuePositions we coverFiledReport
Q3 2026$761.7M1326 Oct 202613F-HR
Q2 2026$798.7M136 Aug 202613F-HR
Q1 2026$652.4M1413 May 202613F-HR
Q4 2025$555.0M1513 Feb 2026amended 18 Mar 202613F-HR/A
Q3 2025$503.9M1713 Nov 2025amended 18 Mar 202613F-HR/A
Q2 2025$334.1M1722 Jul 202513F-HR
Q1 2025$341.9M177 May 202513F-HR
Q4 2024$386.1M1713 Feb 202513F-HR
Q3 2024$427.3M1613 Nov 202413F-HR
Q2 2024$400.7M179 Aug 202413F-HR
Q1 2024$4.4B1410 May 202413F-HR
Q4 2023$4.4B1414 Feb 202413F-HR
Q3 2023$271.5M149 Nov 202313F-HR
Q2 2023$322.1M132 Aug 202313F-HR
Q1 2023$307.4M1411 May 202313F-HR
Q4 2022$0139 Feb 202313F-HR
Q3 2022$339.8M1310 Nov 202213F-HR
Q2 2022$391.5M1310 Aug 202213F-HR
Q1 2022$529.0M139 May 202213F-HR
Q4 2021$878.4M1414 Feb 202213F-HR
Q3 2021$1.1B1412 Nov 2021amended 16 Nov 202113F-HR/A

Holdings at the end of Q3 2026

13, by value
#CompanySharesValue% of portfolio The position's value as a share of the reported value of the whole report. % of company Shares held as a share of the company's shares outstanding (latest financial report). Change vs Q2 2026
1Protagonist Therapeutics PTGX2.4M$345.1M45%3.8%No change
2MeiraGTx MGTX6.6M$73.1M9.6%6.8%No change
3Rapport Therapeutics RAPP1.8M$60.0M7.9%3.0%No change
4Contineum Therapeutics CTNM2.0M$26.6M3.5%8.6%No change
5Cerebras Systems CBRS129K$22.9M3.0%+75K140%
6Xencor XNCR748K$18.7M2.5%1.00%No change
7Fate Therapeutics FATE3.4M$8.0M1.1%2.8%No change
8CVRx CVRX4.0M$7.0M0.92%14%No change
9PROCEPT BioRobotics PRCT358K$6.5M0.86%0.62%No change
10Neumora Therapeutics NMRA1.8M$1.1M0.14%0.98%No change
11Vor Biopharma VOR54K$1.0M0.13%0.09%No change
12Standard BioTools LAB312K$231K0.03%0.08%No change
13Adicet Bio ACET23K$163K0.02%0.24%No change

Bought and sold in Q3 2026

Compared with its Q2 2026 report. Share changes valued at the quarter-end price.

New positions 0

None.

Sold out 0

None.

Biggest decreases 0

None.

Sector mix

Share of the value in companies we cover, Q3 2026 against Q2 2026
SectorQ3 2026As a barQ2 2026Change
Health Care96%98%-1.9 pts
Technology4.0%2.1%+1.9 pts

The bar is Q3 2026; the tick marks Q2 2026.

From Form 13F: long positions in US-listed shares and options at the quarter end, filed up to 45 days later; short positions are not reported. Values are in dollars (reports filed before 2023 were in thousands and are converted). Measures activity, not value. Not investment advice.